FDA claims trial 'manipulation' tainted approval of ChemoCentryx drug

April 28, 2026 09:09 AM EDTUpdated 02:22 PM PharmaFDA+ Up­dat­ed: FDA claims tri­al 'ma­nip­u­la­tion' taint­ed ap­proval of Chemo­Cen­tryx drug now owned by Am­gen Lei Lei Wu News Reporter The FDA ac­cused Chemo­Cen­tryx of ma­nip­u­lat­ing the re­sults of a piv­otal clin­i­cal tri­al used to ap­prove the drug Tavneos, es­ca­lat­ing the agency’s ef­fort to pull … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER